Nevro Corp.President and CEO Rami Elghandour started his company presentation at this year's J.P. Morgan Healthcare Conference on a high note by announcing that US FDA has given the nod of approval for the firm's next-generation Senza II spinal cord stimulation system, and noted that he expects more growth opportunities ahead for 2018.
"We see ample opportunity in 2018," Elghandour told the audience at the Jan
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?